| Israel | Turki | Austria | |
| Operasi kanker lambung | dari $28,500 | dari $22,320 | dari $30,000 |
| Gastrektomi | dari $24,500 | dari $18,300 | dari $25,000 |
| Esofagektomi | dari $14,032 | dari $23,400 | dari $30,000 |
| Reseksi esofagus | - | dari $21,600 | - |
| Omentektomi | - | dari $4,500 | dari $15,000 |
Bookimed tidak menambah biaya tambahan dalam harga Operasi kanker lambung. Tarif berasal dari daftar harga resmi klinik. Anda membayar langsung di klinik untuk Operasi kanker lambung Anda saat tiba.
Bookimed berkomitmen pada keselamatan Anda. Kami hanya bekerja dengan institusi medis yang menjaga standar internasional tinggi dalam Operasi kanker lambung dan memiliki izin yang dibutuhkan untuk melayani pasien internasional di seluruh dunia.
Bookimed menawarkan bantuan ahli gratis. Koordinator medis pribadi mendukung Anda sebelum, selama, dan setelah perawatan, menyelesaikan semua masalah Anda. Anda tidak pernah sendirian dalam perjalanan Operasi kanker lambung Anda.
Dr. Arnon Nagler is an internationally recognized hematologist and bone marrow transplant expert. He is a Professor of Medicine at Tel Aviv University. He is Director Emeritus of Hematology & Bone Marrow Transplantation and the Cord Blood Bank at Sheba Medical Center. He earned his M.D. from the Hebrew University–Hadassah and an M.Sc. in hematopoiesis from Tel Aviv University. He completed postdoctoral training at Stanford. He is board certified in internal medicine and hematology.
He has more than 35 years of experience. He pioneered reduced‑intensity allogeneic transplant protocols for malignant and non‑malignant diseases. He founded Israel’s first public cord blood bank. He performed the country’s first cord blood transplants.
He has held international leadership roles. He served as Chair and Co‑Chair of the ALWP of the EBMT. He was a vice‑chair and long‑term member of EBMT committees. He served on the board of NetCord/EuroCord and as treasurer. He is a frequent invited speaker. He has published widely in journals such as Blood and Leukemia. He has led major clinical trials as a principal investigator and held editorial roles. He has received multiple awards for innovation and clinical excellence.
Prof. Ido Nachmany heads the Second Surgical Department at Sheba Medical Center. He specializes in HPB and robotic surgery for diseases of the liver, pancreas, and bile ducts, and for gastrointestinal neuroendocrine tumors. He also performs adrenal, spleen, and stomach surgery. Forbes listed him among Israel’s top physicians.
He advances minimally invasive robotic and laparoscopic techniques. The aim is better precision and faster recovery.
Credentials: Senior Lecturer at Tel Aviv University. Member of ASTS and IHPBA. Completed HPB and abdominal transplant fellowships at the Thomas E. Starzl Transplantation Institute. Board certified in General Surgery (Israel), Abdominal Organ Transplantation (ASTS), and HPB Surgery (University of Pittsburgh). He has published in Cancer Research, the Journal of the American College of Surgeons, and the European Journal of Surgical Oncology.
Dr. Almog Ben-Yaacov is an Attending Surgeon in the Department of General and Oncological Surgery (Surgery C) at Sheba Medical Center. He specializes in cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). His clinical focus includes gastric cancer, sarcoma, and complex colorectal malignancies. Since 2018, he has performed more than 200 HIPEC procedures.
MD, Semmelweis University, 2006, with honors. Training in cardiothoracic surgery at Sheba Medical Center. Residency in general surgery at Montefiore (Albert Einstein) and at Rabin (Beilinson). Board-certified in General Surgery and in Surgical Oncology.
Advanced training includes ESSO-certified HIPEC in Hamburg. Microwave liver ablation in Reims. NanoKnife at King’s College London. Advanced surgical oncology at Memorial Sloan Kettering (2019). His publications cover CRS+HIPEC outcomes and Hartmann’s reversal.
Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.
He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.
He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.